This clinical event is common in patients with detectable serum HBsAg and lower in individuals with isolated anti-HBc antibodies, and the severity of hepatic damage may range from HBV reactivation without hepatitis to fulminant hepatic failure requiring liver transplantation. The gene discussed is KRT88P; the disease is Fulminant hepatic failure.